1
|
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
|
N Engl J Med
|
2007
|
39.39
|
2
|
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2009
|
13.52
|
3
|
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
|
Nat Rev Clin Oncol
|
2011
|
3.58
|
4
|
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.
|
Br J Cancer
|
2014
|
2.26
|
5
|
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
|
Eur Urol
|
2014
|
2.23
|
6
|
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
|
Clin Cancer Res
|
2015
|
1.53
|
7
|
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
|
Nat Rev Clin Oncol
|
2012
|
1.37
|
8
|
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.
|
Br J Cancer
|
2013
|
1.24
|
9
|
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
|
Br J Cancer
|
2010
|
1.13
|
10
|
A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.
|
Curr Cancer Drug Targets
|
2012
|
1.12
|
11
|
Ten years of anti-vascular endothelial growth factor therapy.
|
Nat Rev Drug Discov
|
2016
|
1.03
|
12
|
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
|
Oncologist
|
2011
|
0.97
|
13
|
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
|
Eur Urol
|
2015
|
0.92
|
14
|
Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU.
|
Br J Clin Pharmacol
|
2016
|
0.91
|
15
|
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
|
Br J Cancer
|
2012
|
0.87
|
16
|
Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.
|
Eur Urol
|
2015
|
0.84
|
17
|
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
|
PLoS One
|
2014
|
0.83
|
18
|
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
|
Cancer Res Treat
|
2015
|
0.79
|
19
|
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.
|
J Clin Oncol
|
2016
|
0.76
|
20
|
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs.
|
Oncotarget
|
2016
|
0.75
|
21
|
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
|
Eur Urol
|
2016
|
0.75
|